Monopar’s stock gains 13% after completing enrollment for an experimental therapy for cancer patients

Shares of Monopar Therapeutics Inc. MNPR, +12.35% gained 13.5% in premarket trading on Wednesday after the company said it completed enrollment in a Phase 2b clinical trial evaluating its experimental therapy aimed at preventing severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. Monopar expects to have interim data from this study in the first quarter of next year. The company’s stock has declined 47.0% so far this year, while the broader S&P 500 SPX, -1.00% is down 20.4%.